MyFinsight
Home
Blog
About
Cash and cash
equivalents
$41,233,428
(149.41%↑ Y/Y)
Prepaid expenses and
other current assets
$679,686
(72.07%↑ Y/Y)
Total current assets
$41,913,114
(147.61%↑ Y/Y)
Other noncurrent
assets
$271,162
(0.00%↑ Y/Y)
Property and equipment,
net
$64,033
(-9.39%↓ Y/Y)
Restricted cash
$41,615
(2.32%↑ Y/Y)
Total assets
$42,289,924
(144.31%↑ Y/Y)
Total liabilities and
stockholders' equity
$42,289,924
(144.31%↑ Y/Y)
Total stockholders'
equity
$38,470,261
(186.78%↑ Y/Y)
Total current
liabilities
$3,092,302
(-2.38%↓ Y/Y)
Series a convertible
preferred stock, 0.001 par...
$727,361
(0.00%↑ Y/Y)
Accumulated deficit
-$340,520,662
(-3.75%↓ Y/Y)
Accumulated other
comprehensive loss
-$10,617,617
(0.10%↑ Y/Y)
Additional paid-in capital
$389,596,149
(10.60%↑ Y/Y)
Accrued expenses
$2,157,163
(9.40%↑ Y/Y)
Accounts payable
$935,139
(-21.80%↓ Y/Y)
Common stock, 0.001 par
value, 400,000,000...
$12,391
(115.42%↑ Y/Y)
Back
Back
Balance Sheet
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)
source: myfinsight.com